Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — H1 2022 Earnings Presentation
27 slides from Marinomed Biotech's earnings presentation, Aug 25, 2022
Slide 1: Investor Presentation H1 2022
Investor Presentation H1 2022 Andreas Grassauer, CEO, Pascal Schmidt, CFO 25th August 2022
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials H1 2022 Pascal Schmidt, CFO • Marinomed strategy Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Highlights in 2022 to date
Highlights in 2022 to date Delivering on our promises Jan. – New CBO Cornelia Kutzer Feb. – €6m EIB financing tranche after meeting all predefined milestones Apr. – New agreement with Hanmi for marketing of Carragelose in South Korea Apr. – Strong 2021 financials and record sales in Q1/22 May – Proc
Slide 5: This keeps us busy
This keeps us busy Various projects require significant attention, but are rewarding • Delays through strict lock-downs in Co-development and definition Execution with Luoxin for the Chinese territory Shanghai of regulatory path • Very constructive collaboration …with the following partners: • Makin
Slide 6: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials H1 2022 Pascal Schmidt, CFO • Marinomed strategy Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 6
Slide 7: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and upfront from first Marinosolv-deal Y-o-Y comparison of quarterly revenues (m€) Comments 13.3* Key growth drivers 9.1 • Revenues rose from €3.2m to €4.9m (+52%) 5.9* • Solv4U generated other revenues 2.8 2.5 3.1 2.2 2.4 2.5 1.0 New busine
Slide 8: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – improved EBIT €m H1 2022 H1 2021 1 H1 2022 H1 2021 Sale of goods 4.6 3.0 Revenues 1 4.9 3.2 Cost of goods sold -3.1 -2.0 Other income 2 0.5 1.3 Margin 32.5% 35.4% Materials expenses -3.2 -2.2 •2 Primarily consisting of research premium and grant S
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m H1 2022 FY 2021 •1 Includes fully recognized headquarter, incl. land and building (€5.6m) therein directly R&D related* (€0.5m) Assets Intangible assets 1.9 2.0 2 Inventories €m H1 2022 FY 2021 Property, plant and equipment 1 6.3 6.4 Goods for sale 0.
Slide 10: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m H1 2022 FY 2021 •1 Capital increases through convertible note funding program Equity and liabilities Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m) and ERP/aws and NÖBEG real estate refinancing (€4.8m) Capital reserves
Slide 11: Comfortable cash reach
Comfortable cash reach Low cash drain due to profitable revenues and inflows from convertible bond program • Ended December 2021 with €5.8m in cash • Raised +€7.3m in net cash through EIB (€6.0m), NÖBEG (€0.2m) and CNFP1 (€1.2m) • Received +€0.7m in milestones • Earned +€1.9m net cash through profit
Slide 12: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials H1 2022 Pascal Schmidt, CFO • Marinomed strategy Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 12
Slide 13: Marinomed investment highlights
Marinomed investment highlights Transforming lives of people living with diseases with limited or no treatment options • Short term growth perspective with existing product portfolio • Therapies for diseases with unmet medical need in the therapeutic areas of virology and immunology • Lean and effic
Slide 14: Marinomed Strategy
Marinomed Strategy Maximizing Expansion Sustainable OTC portfolio revenues of Rx pipeline Therapies Carragelose cashflows Tacrosolv for anterior Reduction of ingredients inflammatory eye diseases Diseases with high unmet Budesolv in other regions Inhaleen for viral medical need Roll-ou
Slide 15: Actions for further growth and future success
Actions for further growth and future success Segment Virology/Carragelose • New partners, such as Procter & Gamble (USA), Hanmi Pharmaceutical (Korea) und M8 (Brasil and Mexico) • New launches • New Chief Business Officer Cornelia Kutzer © Marinomed Biotech AG 15
Slide 16: Marinomed has built a proven track record
Marinomed has built a proven track record Successes in the therapeutic areas Immunology Virology • First aqueous steroid solution, all other major • Discovery of the viral efficacy of Carragelose against competitors are suspensions respiratory viruses • Performance of a series of clinical studies to
Slide 17: Strong pipeline – still more to come
Strong pipeline – still more to come Growth potential to pursue Solid base to build on © Marinomed Biotech AG 17
Slide 18: Tacrosolv validated in clinical phase II trial
Tacrosolv validated in clinical phase II trial1 Anti-inflammatory activity in model indication allergic conjunctivitis shown1 Significant reduction of TOSS* 26% reduction of TOSS* on day 8 on day 8 compared to placebo within Tacrosolv study group 6 after 3.5 hrs2 compared to day 12 5 Placebo Tacroso
Slide 19: Herpetic stromal keratitis
Herpetic stromal keratitis Potentially blinding condition characterized by recurrent infections of the cornea HERPETIC STROMAL KERATITIS (HSK) • Pathology caused by • a local viral cytopathic effect induced by herpetic viruses (mainly Herpes simplex) AND • host immunological and reparative response
Slide 20: Reference Study: add-on therapy with tacrolimus in HSK
Reference Study1: add-on therapy with tacrolimus in HSK Primary and key secondary endpoints were met Treatment plan CORNEAL HAZINESS CORNEAL EDEMA All patients Oral antiviral treatment 400 mg Acylovir tablets • twice daily for interstitial keratitis • five times daily if accompanied by iridocyclitis
Slide 21: Tacrosolv Development Plan 2022/23
Tacrosolv Development Plan 2022/23 Estimated Timelines 2022 (H2) 2022/23 2023 (H1) Apply for Orphan Drug Pharmaceutical Preclinical development Designation development • 14-days local tolerance • Start preparing the application • Preparation for clinical study process at EMA with a full service CRO
Slide 22: Outlook and timeline 2022/2023
Outlook and timeline 2022/2023 News flow / milestones • January – Strengthening business development through new CBO Cornelia Kutzer • February – Draw down of €6m EIB financing tranche • April – New agreement with Hanmi for marketing of Carragelose in South Korea News flow to • April – Publication o
Slide 23: The Marinomed story
The Marinomed story Transforming lives of people living with diseases with limited or no treatment options • Highly experienced management • Short-term and long-term growth perspective • Therapies for diseases with unmet medical need • Lean and efficient business model • Sustainable therapies © Mari
Slide 24: Agenda
Agenda • Highlights to date Andreas Grassauer, CEO • Financials H1 2022 Pascal Schmidt, CFO • Marinomed strategy Andreas Grassauer, CEO • Update on key projects • Investment highlights & outlook • Financial calendar, contact © Marinomed Biotech AG 24
Slide 25: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar Stephanie Kniep August 25, 2022 Publication of the Results H1 2022 Investor Relations phone: +43 2262 90300 226 November 21, 2022 Publication of the Results Q1-Q3 2022 e-mail: IR@marinomed.com © Marinomed Biotech AG 25
Slide 26: Thank you!
Thank you! © Marinomed Biotech AG 26
Slide 27: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Develop products containing less API – for patients and for the environment • Use more renewable energy • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people living with diseases with limi